Oxford Glycosciences has named David Ebsworth CEO effective July 1, 2002, the company said last week. Ebsworth will replace Michael Kranda, who is leaving the company for family reasons, the company said in March. Ebsworth most recently served as head of the worldwide pharmaceutical business group of Bayer.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.